Skip to content
homeHOME R&D Mission & Vison R&D Pipeline

R&D Pipeline

YRI enhances success rates and maintains an innovative drug pipeline by adopting a strategy that focuses on critical areas of unmet medical need. Currently, the main areas of focus include cardiovascular and metabolic diseases, inflammatory and immune disorders, and cancer. YRI continually enriches its competitive drug pipeline by establishing collaborative partnerships with academic research centers, bio-ventures, and government-funded research institutes worldwide. A strong development pipeline further strengthens YRI’s global outreach capacity by expanding potential licensing agreements.

Gastrointestinal Disorder

Gastrointestinal Disorder
Product Indication Preclinical1 Preclinical2 Preclinical3 P1 P2 P3

YH12852

X

pipeline popup
Disease group Gastrointestinal Disorder
Target indications functional dyspepsia, chronic constipation
Stages of development P2
The type of material NCE
Mechanism of Action 5-HT4 agonist
Link
File

Metabolic disorder

Metabolic disorder
Product Indication Preclinical1 Preclinical2 Preclinical3 P1 P2 P3

YH22189

X

pipeline popup
Disease group Metabolic disorder
Target indications hypertension/hyperlipidemia
Stages of development P1
The type of material IMD
Mechanism of Action fixed dose combination
Link
File

YH22162

X

pipeline popup
Disease group Metabolic disorder
Target indications hypertension
Stages of development P1
The type of material IMD
Mechanism of Action fixed dose combination
Link
File

YH25723

X

pipeline popup
Disease group Metabolic disorder
Target indications diabetes
Stages of development Preclinical2
The type of material biologics
Mechanism of Action recombinant protein
Link
File

YH14617

X

pipeline popup
Disease group Metabolic disorder
Target indications diabetes
Stages of development P3
The type of material IMD
Mechanism of Action new formulation
Link
File

YH14755

X

pipeline popup
Disease group Metabolic disorder
Target indications hyperlipidemia/diabetes
Stages of development P3
The type of material IMD
Mechanism of Action fixed dose combination
Link
File

YH18406

X

pipeline popup
Disease group Metabolic disorder
Target indications diabetes
Stages of development Preclinical3
The type of material NCE
Mechanism of Action GPCR agonist
Link
File

YH25348

X

pipeline popup
Disease group Metabolic disorder
Target indications diabetes
Stages of development Preclinical2
The type of material Biologics
Mechanism of Action recombinant protein
Link
File

Immunology / Inflammation

Immunology / Inflammation
Product Indication Preclinical1 Preclinical2 Preclinical3 P1 P2 P3

YH-siRNA2

X

pipeline popup
Disease group Immunology/Inflammation
Target indications psoriasis, cancer
Stages of development Preclinical1
The type of material
Mechanism of Action siRNA
Link
File

YH-siRNA1

X

pipeline popup
Disease group Immunology/Inflammation
Target indications IPF, keloid
Stages of development Preclinical2
The type of material
Mechanism of Action siRNA
Link
File

YH-NCE3

X

pipeline popup
Disease group Immunology/Inflammation
Target indications Grave's orbitopathy
Stages of development Preclinical1
The type of material NCE
Mechanism of Action anti-inflammation
Link
File

YH-BIO

X

pipeline popup
Disease group Immunology/Inflammation
Target indications Grave's orbitopathy
Stages of development Preclinical2
The type of material biologics
Mechanism of Action recombinant protein
Link
File

YH-NCE2

X

pipeline popup
Disease group Immunology/Inflammation
Target indications psoriasis
Stages of development Preclinical1
The type of material NCE
Mechanism of Action immunomodulator
Link
File

YH14618

X

pipeline popup
Disease group Immunology/Inflammation
Target indications digenerative disk disorder
Stages of development P2
The type of material NCE
Mechanism of Action TGF-beta modulator
Link
File

YH1177

X

pipeline popup
Disease group Immunology/Inflammation
Target indications otitis media
Stages of development Preclinical3
The type of material IMD
Mechanism of Action Fixed dose combination
Link
File

YH23537

X

pipeline popup
Disease group Immunology/Inflammation
Target indications periodontitis, arthritis
Stages of development P2
The type of material herbal medicine
Mechanism of Action
Link
File

YH-NCE1

X

pipeline popup
Disease group Immunology/Inflammation
Target indications COPD
Stages of development Preclinical2
The type of material NCE
Mechanism of Action anti-inflammation
Link
File

Oncology

Oncology
Product Indication Preclinical1 Preclinical2 Preclinical3 P1 P2 P3

YH-siRNA3

X

pipeline popup
Disease group Oncology
Target indications cancer
Stages of development Preclinical2
The type of material
Mechanism of Action siRNA
Link
File

YH25448

X

pipeline popup
Disease group Oncology
Target indications cancer
Stages of development Preclinical2
The type of material NCE
Mechanism of Action targeted therapy
Link
File

YH-NCE4

X

pipeline popup
Disease group Oncology
Target indications cancer
Stages of development Preclinical2
The type of material NCE
Mechanism of Action immuno-oncology
Link
File

YH24931

X

pipeline popup
Disease group Oncology
Target indications cancer
Stages of development Preclinical3
The type of material biologics
Mechanism of Action recombinant protein
Link
File